Incretin receptor research
Tirzepatide
Dual GIP / GLP-1 receptor agonist peptide
Account required· quoted per order
Size
| Molecular formula | C225H348N48O68 |
|---|---|
| Sequence | 39 aa (Aib-modified, C20 diacid) |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC / MS) |
| Storage | −20 °C, protect from light |
| Use | Laboratory research only |
For laboratory research use only. Not for human or veterinary use. Not a drug, supplement, or cosmetic. No dosing, administration, or use guidance is provided.
About this compound
Identity & research context
A 39-residue synthetic peptide structurally derived from the human GIP sequence, incorporating Aib residues and a C20 fatty-diacid side chain that confers co-agonist activity at both the GIP receptor and GLP-1 receptor. It is investigated in preclinical and in-vitro model systems as a tool compound for characterizing dual incretin-receptor pharmacology and downstream signaling.
Key research points
- Glucose-regulation pathways (animal / islet models)
- Body-weight & energy-balance endpoints (rodent models)
- Appetite-signaling & gastric-emptying pathways (preclinical)
- Cardiometabolic-marker research (lipid, blood-pressure)
References
For research purposes only. Not FDA approved. Information shown is sourced from published peer-reviewed literature for educational reference only — not medical advice or product claims. Read the full disclaimer.
Also in the catalog
View all